key: cord-0799880-63j91r2a
authors: Hanna, D.; Halliday, E.; Needleman, S.
title: Preparing Breast Cancer Patients for Radiotherapy Treatment in the COVID-19 Era
date: 2022-04-30
journal: Clinical Oncology
DOI: 10.1016/j.clon.2021.12.032
sha: e428aee4bbc0a73855dabfb148690e8776d1d26b
doc_id: 799880
cord_uid: 63j91r2a

nan

Purpose: The COVID-19 pandemic transformed cancer care, with oncologists trying to balance the benefits of SACT against the risk of COVID-19 infection and mortality. Our study compares the demographic and treatment characteristics of BC patients treated at Guy's Cancer Centre during the first wave of the pandemic with the same period in 2019. Methods: We conducted a retrospective analysis of all BC patients who received SACT from 1 March 2020 until 31 May 2020 and compared the demographic (age, ethnicity, socioeconomic and performance status), cancer (stage) and SACT characteristics (type, intent and line of treatment) with those from the same period in 2019. Results: In 2020, 571 BC patients received SACT during the study period, compared with 595 in 2019. Demographic characteristics were equally balanced between both years. The cancer stage, type of treatment and treatment paradigm were also similar (stage IeIII: 49.8% versus 50.9%; chemotherapy: 29.8% versus 30.8%; palliative treatment: 49.9% versus 46.6%, in 2020 and 2019, respectively). However, a larger proportion of patients received first-line palliative treatment in 2020 compared with 2019 (38.6% versus 14.8%). The overall mortality rate was 3.15% in 2020 versus 4.36% in 2019. 11 BC patients were diagnosed with COVID-19 in 2020. From these patients, 10 were receiving chemotherapy and 7 were treated with palliative intent. 9 patients developed severe pneumonia and there was 1 COVID-19related death. Conclusion: Our study shows that there were no significant differences in patient characteristics during the first wave of the pandemic, compared with a similar period in 2019, although numerically fewer patients were treated in 2020 and there was a focus on first-line palliative treatment, rather than subsequent lines. Moreover, it demonstrated that SACT during the pandemic was relatively safe. However, this study might not reflect the decrease in the number of new referrals owing to the pandemic. Purpose: Undergoing radiotherapy treatment for breast cancer can be a daunting and anxiety-provoking experience. Evidence shows that empowering patients with education prior to commencing treatment can have a positive impact on their anxiety levels [1, 2] . We aimed to educate this patient cohort through the development of a video to reinforce information delivered at consultation regarding the treatment process and side-effects of breast radiotherapy. Conclusion: There was greater prescribing of OFS in pre-menopausal women with higher stage breast cancer. These women were also more likely to have received chemotherapy. The use of OFS and choice of AI or tamoxifen was not affected by HER-2 status. We saw variation in prescribing according to treating physician, highlighting the requirement for local guidelines in the management of these patients.

Tailoring adjuvant endocrine therapy for premenopausal breast cancer

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guidelines Focused Update